Home > Boards > US Listed > Miscellaneous > CryoPort Inc. (CYRX)

Although the company doesn’t provide revenue forecasts, I

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hyperopia Member Profile
 
Followed By 6
Posts 261
Boards Moderated 0
Alias Born 09/10/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/9/2019 12:20:08 PM
Cryoport Authorizes Share Repurchase Program and Presenting at Upcoming Investor Conferences PR Newswire (US) - 10/9/2019 9:00:00 AM
Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies GlobeNewswire Inc. - 10/9/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 7:15:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 7:12:18 PM
Cryoport Introduces Cell & Gene Industry's First Dedicated Shipper for Advanced Therapies PR Newswire (US) - 9/18/2019 8:30:00 AM
Vineti and Cryoport Collaborate to Bring Integrated Solutions to the Global Regenerative Therapy Market GlobeNewswire Inc. - 9/4/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/20/2019 12:36:26 PM
BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire Inc. - 8/12/2019 6:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 5:21:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 3:52:49 PM
Cryoport to Report Second Quarter 2019 Financial Results on August 8th, 2019 PR Newswire (US) - 7/25/2019 8:30:00 AM
Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain PR Newswire (US) - 7/11/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/10/2019 5:25:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2019 7:43:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2019 7:42:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/24/2019 5:21:27 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/20/2019 5:30:08 PM
Cryoport Announces Pricing of Public Offering of Common Stock PR Newswire (US) - 6/19/2019 9:02:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/19/2019 5:11:53 PM
Cryoport Announces Proposed Public Offering of Common Stock PR Newswire (US) - 6/19/2019 4:03:00 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/14/2019 5:06:52 PM
CalAmp Announces Research Collaboration with Cryoport to Develop Next Generation Condition Monitoring System PR Newswire (US) - 5/16/2019 8:00:00 AM
Cryoport Expands into Biostorage through the Acquisition of Cryogene PR Newswire (US) - 5/14/2019 5:22:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 5:12:37 PM
hyperopia   Friday, 03/08/19 12:15:11 PM
Re: CYRXorbust post# 11582
Post # of 11931 

Although the company doesn’t provide revenue forecasts, I would like to point out that I did. And I was pretty damn close. . .

Cryoport reported quarterly revenue of 4.0M, 4.6M, 5.3M, 5.7M, and 19.6M for the year. And reported 2.1M in commercial revenue for the year.

Now here’s my post from a year ago:

hyperopia   Wednesday, 03/14/18 10:13:28 AM
Re: Rev3lation post# 11146
Post # 11149 of 11580

. . . I look at the clinical trials, animal health and reproductive as the base-line revenue, which grew about 50% overall last year. . If this continues at this rate, that alone would be $18M for 2018. If it only grows at 40% then it would be $16.8M, and if it increases to 60% it would be $19.2M. To be conservative,I think it will be at the lower end of this range - say $17M. Then the question is: how much will commercial revenue add to this baseline? I’m being conservative and currently estimating only about $2M for the year, for total revenues in 2018 of $19M. I have lowered this estimate twice; from $23M to $21M after last quarter’s conference call and then from $21M to $19M after this last call. Right now my model shows these quarterly estimates for 2018: Q1 3.52 Q2 4.31 Q3 5.23 Q4 5.9 = 18.96. This represents my conservative estimate, and I have run a range of scenarios and hope to revise this estimate upward as we get further updates throughout the year


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist